MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kitamura, Y.
Right arrow Articles by Taniguchi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kitamura, Y.
Right arrow Articles by Taniguchi, T.

Vol. 54, Issue 6, 1046-1054, December 1998

Protective Effects of the Antiparkinsonian Drugs Talipexole and Pramipexole against 1-Methyl-4-phenylpyridinium-Induced Apoptotic Death in Human Neuroblastoma SH-SY5Y Cells

Yoshihisa Kitamura, Tadashi Kosaka, Jun-Ichi Kakimura, Yasuji Matsuoka, Yasuko Kohno, Yasuyuki Nomura, and Takashi Taniguchi

Department of Neurobiology (Y.Ki., T.K., J.K., Y.M., T.T.), Kyoto Pharmaceutical University, Kyoto 607-8412, Japan, Product Management Department (Y.Ko.), Marketing Division, Nippon Boehringer Ingelheim, Hyogo 666-0193, Japan, and Department of Pharmacology (Y.N.), Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

Treatment of human neuroblastoma SH-SY5Y cells with 1 mM 1-methyl-4-phenylpyridinium (MPP+) for 3 days induced production of reactive oxygen species (ROS), followed by caspase-3 activation, cleavage of poly(ADP-ribose) polymerase (PARP), and apoptotic cell death with DNA fragmentation and characteristic morphological changes (condensed chromatin and fragmented nuclei). Simultaneous treatment with 1 mM talipexole slightly inhibited the MPP+-induced ROS production and apoptotic cell death. In contrast, pretreatment with 1 mM talipexole for 4 days markedly protected the cells against MPP+-induced apoptosis. However, this protective effect might not be mediated by dopamine receptors. The talipexole pretreatment induced an increase in antiapoptotic Bcl-2 protein level but had no effect on levels of proapoptotic Bax, Bak, and Bad. It also inhibited MPP+-induced ROS production, p53 expression, and cleavages of caspase-3 and PARP. Similarly, pramipexole pretreatment increased Bcl-2 and inhibited MPP+-induced apoptosis. Although pretreatment with bromocriptine also had a protective effect against MPP+-induced apoptosis, it had no effect on the protein levels of Bcl-2 family members. On the other hand, N6,2'-O-dibutyryl cAMP or calphostin C induced a decreased Bcl-2 level and enhanced MPP+-induced cell death. These results suggest that talipexole has dual actions: (1) it directly scavenges ROS, affording slight protection against MPP+-induced apoptosis, and (2) it induces Bcl-2 expression, thereby affording more potent protection, if it is administrated before MPP+. Pramipexole has similar effects, whereas bromocriptine seems to exhibit the former but not the latter effect.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 NeurologyHome page
A. H.V. Schapira
Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease
Neurology, February 17, 2009; 72(7_Supplement_2): S44 - S50.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Giaime, C. Sunyach, M. Herrant, S. Grosso, P. Auberger, P. J. McLean, F. Checler, and C. A. da Costa
Caspase-3-derived C-terminal Product of Synphilin-1 Displays Antiapoptotic Function via Modulation of the p53-dependent Cell Death Pathway
J. Biol. Chem., April 28, 2006; 281(17): 11515 - 11522.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. A. da Costa, J. Dunys, F. Brau, S. Wilk, R. Cappai, and F. Checler
6-Hydroxydopamine but Not 1-Methyl-4-phenylpyridinium Abolishes {alpha}-Synuclein Anti-apoptotic Phenotype by Inhibiting Its Proteasomal Degradation and by Promoting Its Aggregation
J. Biol. Chem., April 7, 2006; 281(14): 9824 - 9831.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Danzeisen, B. Schwalenstoecker, F. Gillardon, E. Buerger, V. Krzykalla, K. Klinder, L. Schild, B. Hengerer, A. C. Ludolph, C. Dorner-Ciossek, et al.
Targeted Antioxidative and Neuroprotective Properties of the Dopamine Agonist Pramipexole and Its Nondopaminergic Enantiomer SND919CL2x [(+)2-Amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole Dihydrochloride]
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 189 - 199.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Uo, Y. Kinoshita, and R. S. Morrison
Neurons Exclusively Express N-Bak, a BH3 Domain-only Bak Isoform That Promotes Neuronal Apoptosis
J. Biol. Chem., March 11, 2005; 280(10): 9065 - 9073.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. A. LeWitt
Clinical trials of neuroprotection for Parkinson's disease
Neurology, October 12, 2004; 63(7_suppl_2): S23 - S31.
[Full Text]

Home page
 NeurologyHome page
J. E. Ahlskog
Slowing Parkinson's disease progression: Recent dopamine agonist trials
Neurology, February 11, 2003; 60(3): 381 - 389.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. H. V. Schapira
Neuroprotection and dopamine agonists
Neurology, February 1, 2002; 58(90001): S9 - 18.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics